Galapagos NV (NASDAQ:GLPG) Receives Consensus Recommendation of "Reduce" from Analysts

Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) have been given a consensus recommendation of "Reduce" by the eight brokerages that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $25.33.

GLPG has been the subject of a number of research analyst reports. Morgan Stanley lowered Galapagos from an "equal weight" rating to an "underweight" rating and reduced their target price for the company from $31.00 to $22.00 in a report on Friday, February 14th. StockNews.com lowered Galapagos from a "hold" rating to a "sell" rating in a report on Friday. TD Cowen lowered Galapagos from a "strong-buy" rating to a "strong sell" rating in a report on Thursday, January 9th. Finally, Barclays reiterated an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd.

Galapagos Price Performance

Shares of GLPG traded up $0.01 during mid-day trading on Wednesday, reaching $26.87. The company's stock had a trading volume of 603,334 shares, compared to its average volume of 209,090. The business has a fifty day moving average of $25.39 and a 200 day moving average of $26.15. Galapagos has a 1 year low of $22.36 and a 1 year high of $31.23.

Galapagos (NASDAQ:GLPG - Get Free Report) last released its earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($2.24). The firm had revenue of $97.33 million during the quarter, compared to the consensus estimate of $72.22 million. Equities analysts forecast that Galapagos will post -1.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Galapagos

Several institutional investors have recently bought and sold shares of GLPG. R Squared Ltd bought a new position in Galapagos during the fourth quarter valued at about $26,000. GAMMA Investing LLC raised its holdings in Galapagos by 77.4% during the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after buying an additional 974 shares in the last quarter. Wealthquest Corp bought a new position in Galapagos during the first quarter valued at about $74,000. BNP Paribas Financial Markets raised its holdings in Galapagos by 45.9% during the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after buying an additional 2,824 shares in the last quarter. Finally, QRG Capital Management Inc. raised its holdings in Galapagos by 21.7% during the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after buying an additional 1,866 shares in the last quarter. 32.46% of the stock is currently owned by institutional investors.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.